Pure Global
NCT04611932

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

A Randomized, Open-label, Single Dose, 3-period Partial Replicated Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers Under Fasting Conditions
Chong Kun Dang Pharmaceutical·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cardiovascular Disease
Drug/Device/Intervention
CKD-330 Tab. and D090 Tab.
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chong Kun Dang Pharmaceutical
Location
Jeonju, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Nov 11, 2020
End date
Apr 27, 2021
Enrollment
51 participants
Primary outcome

AUCt of CKD-330, D090, CKD-333,Cmax of CKD-330, D090, CKD-333

Summary

This study is a randomized, open-label, single dose, 3-period partial replicated crossover
 study to evaluate the pharmacokinetic profiles and safety of CKD-333 low dose in healthy
 volunteers under fasting conditions.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04611932
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04611932 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chong Kun Dang Pharmaceutical and is currently Not yet recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 51 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.